CANIGEN CH/L

Authorised

- Canine adenovirus 2, strain Manhattan, Live
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
- Canine distemper virus, strain Lederle, Live

Product identification

Medicine name:
CANIGEN CH/L

Active substance:
Canine adenovirus 2, strain Manhattan, Live

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated

Canine distemper virus, strain Lederle, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Canine adenovirus 2, strain Manhattan, Live
10000.00 50% cell culture infectious dose / 1.00 Dose

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
4250.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
4350.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Canine distemper virus, strain Lederle, Live
1000.00 50% cell culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and suspension for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

France

Package description:

Available only in French
Available only in French
Available only in French
Available only in French

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
Virbac

Marketing authorisation date:
7/01/1981

Manufacturing sites for batch release:
Virbac

Responsible authority:
French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:
FR/V/5023663 7/1981

Date of authorisation status change:
29/11/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.